Article

FDA panel recommends approval of new lymphoma drug

Author(s):

Update [Sept. 28]: The FDA approves pralatrexate. Read more...Last winter, we first reported on a promising new drug called pralatrexate for peripheral T-cell lymphoma, and today, a medical advisory panel that makes recommendations to the Food and Drug Administration backed the drug for approval in a 10-4 vote.

Although not always, the FDA typically follows the panel's advice.The drug, made by Allos Therapeutics, would be sold under the brand name Folotyn. The FDA is expected to make its decision by September 24.

Check out our lymphoma feature from the Spring 2009 issue, which includes more about pralatrexate. There's also a pretty cool illustration showing how the drug works.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man.
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Anne M. Reb is a nurse practitioner with City of Hope.
Image of woman with brown hair.
Image of man with black hair.
Image of bald man.
Image of man.
Related Content